Showing results (381-390 of 406) with videos related to

Sort By:
Pageof 41
Haematologica|March 5, 2026
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trialsKatarina Uttervall, Martin K Kortum, Aurore Perrot, et al.
Lancet (London, England)|June 18, 2016
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Eva Hoster, Jan Walewski, et al.
Nature Medicine|June 25, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
The Lancet. Oncology|May 31, 2024
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy CommitteeYi Lin, Lugui Qiu, Saad Usmani, et al.
Leukemia|August 21, 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Mario Boccadoro, Philippe Moreau, et al.
Advances in Therapy|December 19, 2023
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple MyelomaPhilippe Moreau, María-Victoria Mateos, Maria Esther Gonzalez Garcia, et al.
Cancers|September 9, 2023
Outcome of Second Primary Malignancies Developing in Multiple Myeloma PatientsIrit Avivi, David H Vesole, Julio Davila-Valls, et al.
Haematologica|September 3, 2013
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trialChristof Scheid, Pieter Sonneveld, Ingo G H Schmidt-Wolf, et al.
Leukemia|May 4, 2018
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Michel Delforge, Thierry Facon, et al.
Hemasphere|October 15, 2025
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myelomaNiccolò Bolli, Mattia D'Agostino, Tina Bagratuni, et al.
Pageof 41